Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's 40th Annual Meeting
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
One Bullion Reports High Concentration of Gold During Artisanal Sampling Program at Vumba Project Which Yielded a 679 g/t Gold Sample
Oreterra Sells Option to Buy Down Newmont Lake Royalty to Enduro Metals for Shares and Cash, Highlighting Golden Triangle Asset Value
U92 Energy Corp. Provides Corporate Update on Phase One Drilling and Technical Advancement for Its Uranium Project in Guyana
